GlassScriptPhysician profile
Jennifer T Lee
NPI 1083027395
$3,884.69
in general payments reported to CMS, 2019-2025
28 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2022: $2,106 · 2023: $414 · 2024: $369 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,932.33 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $200.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $192.21 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $150.61 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Viiv Healthcare Company | $148.43 | 2025 | Apretude |
| Idorsia Pharmaceuticals US INC | $133.96 | 2023 | Quviviq |
| Abbott Laboratories | $106.82 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $102.65 | 2019 | |
| Genzyme Corporation | $94.26 | 2024 | |
| Novo Nordisk INC | $92.73 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $88.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $74.03 | 2022-2024 | Farxiga, Airsupra |
| Pfizer INC. | $70.40 | 2024-2025 | |
| Astellas Pharma US INC | $58.73 | 2024 | Veozah |
| Exact Sciences Corporation | $57.76 | 2023 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.51 | 2019-2025 | Evenity |
| Phadia US INC. | $49.17 | 2023-2025 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.25 | 2022-2023 | Ofev |
| Sumitomo Pharma America, INC. | $41.55 | 2023 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $35.88 | 2024 | |
| Boston Scientific Corporation | $35.42 | 2025 | General - Pain Management |
| Radius Health, INC. | $21.74 | 2019 | |
| Therapeuticsmd, INC. | $21.21 | 2019 | |
| Organon LLC | $18.83 | 2022 | |
| Baxter Healthcare | $17.28 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Inspire Medical Systems, INC. | $15.50 | 2025 | Inspire |
| Kyowa Kirin, INC. | $15.18 | 2024 | |
| Cequr Corporation | $11.36 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.